CIPROFLOXACIN AND DEXAMETHASONE
Clinical safety rating: caution
Chelates with divalent cations (antacids Ca2+ Fe2+) reducing absorption May enhance effects of warfarin Associated with tendonitis and tendon rupture.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
| Metabolism | Ciprofloxacin undergoes hepatic metabolism via CYP1A2 to several metabolites (e.g., desethylciprofloxacin, sulfociprofloxacin). Dexamethasone is metabolized by CYP3A4 to 6β-hydroxydexamethasone and other metabolites. |
| Excretion | Ciprofloxacin: 50-70% unchanged in urine via glomerular filtration and tubular secretion; 20-35% in feces via biliary and intestinal secretion. Dexamethasone: primarily metabolized, <10% unchanged in urine; biliary/fecal excretion of metabolites. |
| Half-life | Ciprofloxacin: 3.7-4.3 hours (prolonged in renal impairment). Dexamethasone: 3-4 hours. |
| Protein binding | Ciprofloxacin: 20-40% bound to albumin. Dexamethasone: 77% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Ciprofloxacin: 2-3 L/kg (extensive tissue penetration). Dexamethasone: 0.8-1.0 L/kg. |
| Bioavailability | Ciprofloxacin: ophthalmic/otic ~90% (local, minimal systemic absorption). Dexamethasone: ophthalmic/otic <1% systemic absorption. |
| Onset of Action | Otic: symptomatic relief within 24 hours. Ophthalmic: clinical effect within 1-2 days. |
| Duration of Action | Otic: administer twice daily for 7 days; clinical response within 48-72 hours. Ophthalmic: continue for 7-14 days; taper if prolonged use. |
| Molecular Weight | Ciprofloxacin: 331.34 Da; Dexamethasone: 392.46 Da |
4 drops into affected ear(s) twice daily for 7 days. Otic suspension; shake well before use.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific dose adjustment needed. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential ciprofloxacin accumulation; monitor for adverse effects. |
| Liver impairment | No specific dose adjustment needed for Child-Pugh A or B. For severe hepatic impairment (Child-Pugh C), use with caution and monitor for adverse effects. |
| Pediatric use | Children ≥6 months: 4 drops into affected ear(s) twice daily for 7 days. Do not use in neonates <28 days due to risk of adverse events. |
| Geriatric use | No specific dose adjustment; use with caution due to increased risk of adverse effects (e.g., tendonitis, neuropathy). Monitor renal function and hearing. |
| 1st trimester | Fluoroquinolones are generally avoided during the first trimester due to potential risk of arthropathy and cartilage damage based on animal studies; however, otic/ophthalmic use with minimal systemic absorption may be considered if benefit outweighs risk. Dexamethasone is a corticosteroid with minimal systemic absorption when used topically/otically; risk of fetal growth restriction or adrenal suppression is theoretical with maternal systemic use but low risk with ophthalmic/otic preparations. |
| 2nd trimester | Second trimester use of ciprofloxacin is not recommended for systemic use due to possible fetal cartilage damage; safe for otic/ophthalmic use due to negligible systemic absorption. Dexamethasone is generally avoided systemically during pregnancy for chronic use; short-term topical/otic use is considered safe due to minimal absorption. |
| 3rd trimester | Third trimester: ciprofloxacin is avoided systemically; topical/otic use is safe. Dexamethasone may be used systemically for fetal lung maturity under specialist supervision; topical/otic use is safe. Fluoroquinolones cross placenta and may cause fetal cartilage damage; minimal systemic exposure from drops. |
Clinical note
Chelates with divalent cations (antacids Ca2+ Fe2+) reducing absorption May enhance effects of warfarin Associated with tendonitis and tendon rupture.
| FDA category |
■ FDA Black Box Warning
Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture, especially in patients >60 years, those on corticosteroids, and organ transplant recipients. Use should be reserved for conditions with no alternative therapy.
| Common Effects | Nausea |
| Serious Effects |
Hypersensitivity to ciprofloxacin, dexamethasone, or any component of the formulationHypersensitivity to other fluoroquinolones (e.g., norfloxacin, levofloxacin)Viral infections of the eye (e.g., herpes simplex keratitis, vaccinia, varicella) – for ophthalmic useFungal infections of the eye – for ophthalmic useUntreated bacterial infections when no ophthalmic/otic infection present (systemic use)
| Precautions | Tendinitis and tendon rupture, Peripheral neuropathy, Central nervous system effects (e.g., dizziness, seizures), Exacerbation of myasthenia gravis, Clostridioides difficile-associated diarrhea, Photosensitivity, Hypersensitivity reactions |
Loading safety data…
| Animal |
| Placental transfer | Ciprofloxacin crosses the placenta; animal studies show placental transfer with accumulation in fetal tissues. Dexamethasone crosses the placenta and is partially inactivated by placental enzymes; fetal exposure is approximately 20-30% of maternal concentration. When administered as ophthalmic or otic drops, systemic absorption is minimal (<1%), and thus placental transfer is negligible. |
| Breastfeeding | Ciprofloxacin is excreted into breast milk in small amounts; the American Academy of Pediatrics considers it compatible with breastfeeding. Dexamethasone is excreted into breast milk in low concentrations; no adverse effects reported. Otic or ophthalmic use of this combination results in negligible systemic exposure, making breastfeeding risk minimal. However, prolonged systemic therapy with high doses should be avoided; monitor infant for gastrointestinal disturbances (ciprofloxacin) or adrenal suppression (dexamethasone). |
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | First trimester: Ciprofloxacin (FDA category C) associated with arthropathy in juvenile animals; dexamethasone (FDA category C) associated with cleft palate in animal studies. Inadequate human data. Avoid if alternatives exist. Second/third trimesters: Ciprofloxacin not associated with major malformations but may cause fetal cartilage damage; dexamethasone may cause intrauterine growth restriction, adrenal suppression. Weigh risks vs benefits. |
| Fetal Monitoring | Monitor maternal renal and hepatic function; fetal growth ultrasound; consider amniotic fluid index if prolonged use. Monitor neonate for adrenal suppression if dexamethasone used near term. |
| Fertility Effects | Ciprofloxacin: No known human fertility impairment. Dexamethasone: High doses may disrupt ovulatory cycles; effects reversible upon discontinuation. |
| Food/Dietary | No known food interactions for otic ciprofloxacin/dexamethasone. Avoid getting water in the ear during treatment (e.g., swimming, showering with ear protection) to prevent re-infection. |
| Clinical Pearls | This fixed-dose combination (otic suspension) is indicated for acute otitis externa and acute otitis media with tympanostomy tubes. Use for no longer than 7 days to minimize risk of fungal superinfection or bacterial resistance. Avoid in patients with tympanic membrane perforation (non-intact) for the otic suspension due to risk of ototoxicity. For otic use only; not for ophthalmic or systemic use. Shake well before use. Warm bottle in hands to avoid dizziness from cold instillation. |
| Patient Advice | Instill the prescribed number of drops into the affected ear(s) twice daily for 7 days. · Warm the bottle by holding it in your hands for 1-2 minutes before use to prevent dizziness. · Do not touch the dropper tip to the ear, fingers, or any surface to avoid contamination. · Lie on your side with the affected ear facing up for 5 minutes after instillation to allow medication to reach the canal. · Complete the full course even if symptoms improve; do not stop early unless directed by your doctor. · Do not use this medication for any other condition or longer than prescribed. · Contact your doctor if symptoms worsen, do not improve after 3 days, or if new symptoms like ringing in the ear or discharge develop. · Keep bottle tightly closed and store at room temperature away from moisture and heat. |